$GLPG News

Last published 1mo ago

1mo agoGLPG LKFT1773831 - LAKEFRONT BIOTHERAPEUTICS NVEarnings Call TranscriptsGood afternoon, everyone. Welcome to the final fireside of day two at Morgan Stanley's Global Healthcare Conference. I'm Judah Frommer, one of the SMID biotech analysts here. We're very excited to have Henry, Aaron, and
6mo agoGLPGGalapagos Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireGalapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM ((Euronext &, NASDAQ:LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to
6mo agoGLPGGalapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026GlobeNewswireMechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held
7mo agoGLPGGalapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune DiseasesGlobeNewswireNew collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional
7mo agoGLPGGalapagos Announces Nomination of Gino Santini to its Board of DirectorsGlobeNewswireSubject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry
7mo agoGLPGGalapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' MeetingsGlobeNewswireMechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV ((Euronext &, NASDAQ:GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders'
7mo agoGLPGGalapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune DiseasesGlobeNewswireGalapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility
8mo agoGLPG LKFTLEERINK GLOBAL HEALTHCARE CONFERENCE - LAKEFRONT BIOTHERAPEUTICS NVEarnings Call TranscriptsI think it's the morning. Good morning, everyone. This is Dana Graybosch. I'm a senior equity research analyst here at Lyric Partners, and I'm excited to be hosting management from Gilead this morning. We have Dietmar an
8mo agoGLPGGalapagos Creates New Subscription Right PlanGlobeNewswireMechelen, Belgium; March 6, 2026, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a new subscription
8mo agoGLPGGalapagos Appoints Tania Philipp as Chief Human Resources OfficerGlobeNewswireSeasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of
8mo agoGLPGGalapagos Receives Transparency Notifications from Bank of AmericaGlobeNewswireMechelen, Belgium; March 4, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1,
8mo agoGLPG LKFTTD Cowen 46th Annual Health Care Conference - LAKEFRONT BIOTHERAPEUTICS NVEarnings Call TranscriptsThat's exciting. All right. Good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowan. Thank you very much for joining TD Cowans' 46th Annual Healthcare Conference. For our next session, it's a pri
8mo agoGLPGGalapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewswireStrategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business
8mo agoGLPGGalapagos Welcomes Dr. Paulo Fontoura to its Board of DirectorsGlobeNewswireDr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today
8mo agoGLPGGalapagos Receives Transparency Notification from Bank of AmericaGlobeNewswireMechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transparency
9mo agoGLPGGalapagos Receives Transparency Notifications from Bank of AmericaGlobeNewswireMechelen, Belgium; February 10, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency
10mo agoGLPGGalapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy ActivitiesGlobeNewswireMechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed
10mo agoGLPGGalapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus ErythematosusGlobeNewswireGLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the
11mo agoGLPGGalapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025GlobeNewswireHigh complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day
11mo agoGLPGGalapagos Receives Transparency Notifications from Bank of AmericaGlobeNewswireMechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency
1y agoGLPGGalapagos Reports Nine Months 2025 Financial Results and Provides Business UpdateGlobeNewswireStrategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of
1y agoGLPGGalapagos to Present New Data from Cell Therapy Program at ASH 2025GlobeNewswireOral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy
1y agoGLPGGalapagos Announces Changes to its Board to Accelerate Strategic Focus on Business DevelopmentGlobeNewswireNew Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today
1y agoGLPGGalapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 InhibitorsGlobeNewswireMechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in
1y agoGLPGGalapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing TransformationGlobeNewswireIntention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30
1y agoGLPGGalapagos Announces Appointment of Fred Blakeslee as General CounselGlobeNewswireMechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025.
1y agoGLPGGalapagos Provides Update on Strategic Alternatives for Its Cell Therapy BusinessGlobeNewswireMechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its Board of
1y agoGLPGGalapagos Creates New Subscription Right PlanGlobeNewswireMechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a new subscription
1y agoGLPGGalapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell LymphomaGlobeNewswireMechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the United States Food and Drug Administration (FDA) has granted
1y agoGLPGGalapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business TransformationGlobeNewswireAppoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation
1y agoGLPGGalapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of DirectorsGlobeNewswireNew Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments by way
1y agoGLPGGalapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business UpdateGlobeNewswireAppointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion
1y agoGLPGGalapagos Appoints Aaron Cox as Chief Financial OfficerGlobeNewswireFormer Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information –
1y agoGLPGGalapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101GlobeNewswireOf the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing GLPG5101 demonstrated
1y agoGLPGGalapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHLGlobeNewswireData reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the
1y agoGLPGGalapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101GlobeNewswireMechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today
1y agoGLPGGalapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board ChangesGlobeNewswireGalapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell
1y agoGLPGGalapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term CatalystsGlobeNewswireFirst U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start
1y agoGLPG NMRAGalapagos Announces Executive Leadership UpdatesGlobeNewswireMr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the
1y agoGLPGGalapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025GlobeNewswireMechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through
1y agoGLPGGalapagos Publishes 2024 Annual Report and Announces Annual Shareholders' MeetingGlobeNewswireMechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders'
1y agoGLPGGalapagos to Present at Upcoming Investor ConferencesGlobeNewswireMechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today
1y agoGLPGGalapagos receives transparency notification and 13D filing from Tang CapitalGlobeNewswireMechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian
1y agoGLPGGalapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business UpdateGlobeNewswireCompelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on
1y agoGLPGGalapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded EntitiesGlobeNewswireGalapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global
1y agoGLPGGalapagos to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025,
1y agoGLPGGalapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin LymphomaGlobeNewswireData from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96% of patients
2y agoGLPGGalapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024GlobeNewswireNew Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing
2y agoGLPGGalapagos NV (GLPG) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoGLPGGalapagos Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireWe are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small